Video Edwards Lifesciences – Mitral and Tricuspid Therapies at PCR London Valves 2021

Published: 27 November 2021

  • Views:

    Views Icon 21142

  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

Filmed around PCR London Valves 2021, this programme brings together three opinion leaders to discuss the latest in mitral and tricuspid therapies in the Edwards’ portfolio. Chair Prof Philipp Lurz (Heart Center Leipzig of University Leipzig, DE) is joined by Dr Sam Dawkins (John Radcliffe Hospital, Oxford, UK) and Prof Nicole Karam (Georges Pompidou European Hospital University of Paris, FR) to summarise the challenges facing MR and TR, and review latest data supporting strategies to achieve optimal patient outcomes.

This programme is supported by

More from this programme

Part 1

Part 1 – Edwards Lifesciences Mitral and Tricuspid Therapies at PCR London Valves 2021 – Introduction

In this first part, Prof Lurz provides an introduction to Edwards’ transcatheter portfolio, and summarises the pivotal studies underpinning the emergence of a compelling body of clinical evidence supporting both mitral (SAPIEN M3 Valve, EVOQUE Eos valve, PASCAL platform, Cardioband mitral system) and tricuspid (EVOQUE replacement system, Cardioband tricuspid system, and PASCAL platform) portfolios.
1 session
Edwards Lifesciences Mitral and Tricuspid Therapies at PCR London Valves 2021 – Introduction Watch now

Part 2

Part 2 – Seeing is Believing: Predictable and Durable Treatment of MR Across Etiologies With the PASCAL Platform

Dr Dawkins guides us through PASCAL platform experience and outcomes from over 3,800 MR patients, the operator learning curve, and MR reduction rates in real-world settings. He continues to review the finding of MiCLASP at 30-day follow-up, and CLASP study at 2-year follow-up.
1 session
Part 2 – Seeing is Believing: Predictable and Durable Treatment of MR Across Etiologies With the PASCAL Platform Watch now

Part 3

Part 3 – Edwards' Transcatheter Trilogy: An Exclusive Portfolio of Three Options to Treat TR

Prof Karam discusses the challenges and needs for the effective treatment of tricuspid valve disease, and draws upon multi-centre experience to provide insight into the effective use of the PASCAL platform. In addition, Prof Karam summarises significant and sustained annular reduction and consequently TR reduction with Cardioband Tricuspid System, data indicating significant TR reduction in laboratory assessments with the EVOQUE2* Valve.
1 session
Part 3 – Edwards' Transcatheter Trilogy: An Exclusive Portfolio of Three Options to Treat TR Watch now

Faculty Biographies

Philipp Lurz

Philipp Lurz

University Medical Center Mainz, Mainz, Germany

Prof Philipp Lurz is Director of the Department of Cardiology Universitätsmedizin Mainz, Germany. Prior to this, he served as Deputy Head of the Department at Heart Center Leipzig, Germany. Previously, Prof Lurz was a Clinical Research Fellow at Great Ormond Street Hospital for Children NHS Foundation Trust. He completed his education at the University of Leipzig, and is a member of the German Society of Cardiology. Philipp is widely published in leading international peer-reviewed journals.

View full profile